RU2014103498A - Применение агонистических антител против cd83 для лечения аутоиммунных заболеваний - Google Patents
Применение агонистических антител против cd83 для лечения аутоиммунных заболеваний Download PDFInfo
- Publication number
- RU2014103498A RU2014103498A RU2014103498/10A RU2014103498A RU2014103498A RU 2014103498 A RU2014103498 A RU 2014103498A RU 2014103498/10 A RU2014103498/10 A RU 2014103498/10A RU 2014103498 A RU2014103498 A RU 2014103498A RU 2014103498 A RU2014103498 A RU 2014103498A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- hvr
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 8
- 102100035793 CD83 antigen Human genes 0.000 title claims abstract 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 title claims abstract 4
- 230000008484 agonism Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 34
- 229940119218 CD83 agonist Drugs 0.000 claims abstract 16
- 102000004127 Cytokines Human genes 0.000 claims abstract 8
- 108090000695 Cytokines Proteins 0.000 claims abstract 8
- 210000004443 dendritic cell Anatomy 0.000 claims abstract 8
- 230000004913 activation Effects 0.000 claims abstract 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 4
- 230000000770 proinflammatory effect Effects 0.000 claims abstract 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 4
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims abstract 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims abstract 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims abstract 2
- 206010021263 IgA nephropathy Diseases 0.000 claims abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims abstract 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims abstract 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims abstract 2
- 206010036105 Polyneuropathy Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 208000003782 Raynaud disease Diseases 0.000 claims abstract 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims abstract 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims abstract 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims abstract 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims abstract 2
- 206010047115 Vasculitis Diseases 0.000 claims abstract 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 claims abstract 2
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 claims abstract 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract 2
- 210000000066 myeloid cell Anatomy 0.000 claims abstract 2
- 230000007824 polyneuropathy Effects 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 208000011580 syndromic disease Diseases 0.000 claims abstract 2
- 230000003582 thrombocytopenic effect Effects 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 31
- 210000004027 cell Anatomy 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 102000043136 MAP kinase family Human genes 0.000 claims 2
- 108091054455 MAP kinase family Proteins 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 241000084978 Rena Species 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504127P | 2011-07-01 | 2011-07-01 | |
| US61/504,127 | 2011-07-01 | ||
| JP2011285585 | 2011-12-27 | ||
| JP2011285585A JP2013040160A (ja) | 2011-07-01 | 2011-12-27 | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| PCT/US2012/045142 WO2013006505A1 (en) | 2011-07-01 | 2012-06-29 | Use of anti-cd83 agonist antibodies for treating autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014103498A true RU2014103498A (ru) | 2015-08-10 |
Family
ID=47888898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014103498/10A RU2014103498A (ru) | 2011-07-01 | 2012-06-29 | Применение агонистических антител против cd83 для лечения аутоиммунных заболеваний |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9562097B2 (enExample) |
| EP (1) | EP2726509B1 (enExample) |
| JP (2) | JP2013040160A (enExample) |
| KR (1) | KR20140051272A (enExample) |
| CN (1) | CN103906766B (enExample) |
| AU (1) | AU2012279175B2 (enExample) |
| BR (1) | BR112013033968A2 (enExample) |
| CA (1) | CA2840426A1 (enExample) |
| MX (1) | MX2014000142A (enExample) |
| RU (1) | RU2014103498A (enExample) |
| WO (1) | WO2013006505A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013150592A (ja) * | 2011-07-01 | 2013-08-08 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| JP6539585B2 (ja) | 2013-02-01 | 2019-07-03 | デンドロサイト バイオテック ピーティーワイ リミテッド | 抗ｃｄ８３抗体及びその使用 |
| US10870704B2 (en) | 2014-10-23 | 2020-12-22 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
| US9982057B2 (en) | 2014-11-17 | 2018-05-29 | Pelican Therapeutics, Inc. | Human TNFRSF25 antibody |
| CN109320610B (zh) * | 2015-01-27 | 2021-07-27 | 中国科学技术大学先进技术研究院 | 抗人cd83单克隆抗体及其制备、鉴定和应用 |
| CN109219620B (zh) | 2016-06-09 | 2023-01-31 | 派立卡恩治疗公司 | 抗-tnfrsf25抗体 |
| US11192943B2 (en) * | 2017-09-30 | 2021-12-07 | Hefei Lifeon Pharmaceutical Co., Ltd. | Protein binding to fibronectin B domain |
| US12492254B2 (en) * | 2018-02-23 | 2025-12-09 | H. Lee Moffitt Cancer Center and Research Intitute. Inc. | CD83-binding chimeric antigen receptors |
| JP7701908B2 (ja) * | 2019-08-16 | 2025-07-02 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞 |
| AU2020334893A1 (en) * | 2019-08-16 | 2022-02-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
| US20230051885A1 (en) * | 2019-12-18 | 2023-02-16 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Systems and Methods for Producing Efficacious Regulatory T Cells |
| EP3895723A1 (en) * | 2020-04-16 | 2021-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Scd83 for wound healing, hair growth, and skin and hair care |
| EP4598572A1 (en) * | 2022-10-04 | 2025-08-13 | Emergent Product Development Gaithersburg Inc. | Novel vsv virus formulations |
| DE102024110866A1 (de) * | 2024-04-18 | 2025-10-23 | Christian Arnold | Pharmazeutische Zusammensetzung zur Heilung einer Wunde |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2005519586A (ja) | 2001-11-21 | 2005-07-07 | セルテック アール アンド ディー， インコーポレイテッド | Ｃｄ８３遺伝子産物を利用したサイトカイン・レベルの操作法 |
| US20040185040A1 (en) * | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| AU2002950779A0 (en) * | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
| DE60334246D1 (de) * | 2002-11-21 | 2010-10-28 | Celltech R & D Inc | Modulieren von immunantworten |
| US7169898B2 (en) * | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| US8420783B2 (en) * | 2004-12-08 | 2013-04-16 | Immunomedics, Inc. | Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
-
2011
- 2011-12-27 JP JP2011285585A patent/JP2013040160A/ja active Pending
-
2012
- 2012-06-29 EP EP12807315.2A patent/EP2726509B1/en not_active Not-in-force
- 2012-06-29 RU RU2014103498/10A patent/RU2014103498A/ru not_active Application Discontinuation
- 2012-06-29 US US14/129,053 patent/US9562097B2/en not_active Expired - Fee Related
- 2012-06-29 JP JP2014519203A patent/JP6198730B2/ja not_active Expired - Fee Related
- 2012-06-29 AU AU2012279175A patent/AU2012279175B2/en not_active Ceased
- 2012-06-29 BR BR112013033968A patent/BR112013033968A2/pt not_active IP Right Cessation
- 2012-06-29 CA CA2840426A patent/CA2840426A1/en not_active Abandoned
- 2012-06-29 KR KR1020147002210A patent/KR20140051272A/ko not_active Withdrawn
- 2012-06-29 CN CN201280042210.6A patent/CN103906766B/zh not_active Expired - Fee Related
- 2012-06-29 MX MX2014000142A patent/MX2014000142A/es unknown
- 2012-06-29 WO PCT/US2012/045142 patent/WO2013006505A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HK1199271A1 (en) | 2015-06-26 |
| CA2840426A1 (en) | 2013-01-10 |
| MX2014000142A (es) | 2014-04-25 |
| JP6198730B2 (ja) | 2017-09-20 |
| EP2726509A4 (en) | 2015-01-28 |
| CN103906766A (zh) | 2014-07-02 |
| AU2012279175B2 (en) | 2017-02-02 |
| KR20140051272A (ko) | 2014-04-30 |
| EP2726509B1 (en) | 2018-05-02 |
| US20140286950A1 (en) | 2014-09-25 |
| AU2012279175A1 (en) | 2013-05-02 |
| BR112013033968A2 (pt) | 2017-12-12 |
| CN103906766B (zh) | 2017-03-08 |
| EP2726509A1 (en) | 2014-05-07 |
| JP2015511931A (ja) | 2015-04-23 |
| WO2013006505A1 (en) | 2013-01-10 |
| US9562097B2 (en) | 2017-02-07 |
| JP2013040160A (ja) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014103498A (ru) | Применение агонистических антител против cd83 для лечения аутоиммунных заболеваний | |
| JP2015511931A5 (enExample) | ||
| CN109862915B (zh) | 针对信号调控蛋白α的抗体和使用方法 | |
| CA2914170C (en) | Interleukin-13 binding proteins | |
| RU2014147773A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| JP2009519718A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| RU2021133819A (ru) | Анти-lag-3 антитела | |
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2017504314A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| RU2014136332A (ru) | Композиции и способы применения ингибиторов csf1r | |
| RU2011145428A (ru) | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ | |
| CA3088734A1 (en) | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r | |
| CN106459196A (zh) | 抗体、用途和方法 | |
| RU2008152443A (ru) | Антитела высокой аффинности к il-6-рецептору человека | |
| RU2012130840A (ru) | Соединения | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| JP2014500009A5 (enExample) | ||
| EP3265123A1 (en) | Antibodies, uses & methods | |
| JP6466904B2 (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| RU2020111737A (ru) | Антитело против il-6r и его антигенсвязывающий фрагмент и медицинское применение | |
| RU2019111862A (ru) | Новые антитела против фактора xi и их применения | |
| JP2013519690A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20191007 |